98%
921
2 minutes
20
Objective: The Flare Assessment in RA (FLARE-RA) self-administered questionnaire aims to identify patients who had flare in the interval between two consultations. This study aimed to establish a threshold for FLARE-RA score to identify RA flare.
Methods: The Tocilizumab SubCutAneous study evaluated the efficacy and safety of s.c. tocilizumab (TCZ) to patients with active RA. Disease activity was assessed with the DAS28ESR at baseline and at week 2 (W2), W4, W12 and W24. The FLARE-RA questionnaire was administered at W12 and W24. Patient satisfaction, assessed at baseline and W24 with the Patient Acceptable Symptom State (PASS), was used as a surrogate marker of no flare. A correlation was sought between the FLARE-RA score at W12 and W24 and the area under the receiver operating characteristic (ROC) curve (AUC) for monthly DAS28ESR. The optimal FLARE-RA cut-off below which patient satisfaction reached the PASS was explored with an ROC curve.
Results: A total of 139 patients were included (mean age 57.3 ± 13.8 years, 74.1% women, mean RA duration 10.8 ± 9.2 years, mean DAS28ESR 5.8 ± 1.1). The correlation between the FLARE-RA score and DAS28ESR AUC was moderate at all times: ρ = 0.41 at W12 (P < 0.0001) and 0.51 at W24 (P < 0.0001). The optimal cut-off for the FLARE-RA score to identify absence of flare (i.e. an acceptable situation based on the PASS) was 2.3 with an AUC of 0.81.
Conclusion: FLARE-RA and DAS28ESR assessment differ; we propose a FLARE-RA cut-off of 2.3, below which the situation (i.e. without flare) is acceptable for patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rheumatology/keab261 | DOI Listing |
Joint Bone Spine
September 2025
Université de Lorraine, Inserm, UMR INSPIIRE, Nancy, France; CHRU de Nancy, Inserm, Université de Lorraine, CIC Epidémiologie clinique, Nancy, France.
Objective: To describe whether rheumatoid arthritis (RA) flares detected by the self-administered Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire can predict joint structural damage progression at 2 years and to explore the association between the FLARE-RA score and RA outcome measures.
Methods: Adults with RA for less than 10 years and Health Assessment Questionnaire-Disability Index (HAQ-DI) score <1 were included in this prospective observational study. Patients were followed clinically every 6 months and completed the FLARE-RA questionnaire every 3 months at home, for 24 months.
RMD Open
April 2025
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Objectives: Drug withdrawal in rheumatoid arthritis (RA) in remission can reduce toxicity, but with the risk of flare which requires close monitoring. We explored the potential of patient-reported outcomes (PROs) for flare detection among RA patients in sustained remission after conventional synthetic disease-modifying antirheumatic drug (csDMARD) cessation.
Methods: Four PROs (Factors that Limit sustAined Remission in rhEumatoid arthritis (FLARE-RA), EuroQol-5 Dimensions (EQ5D), Routine Assessment of Patient Index Data-3 (RAPID-3) and RA Flare Questionnaire (RA-FQ)) were captured at baseline and at sequential visits until time-of-flare or end of 6-month follow-up as part of the BIO-FLARE prospective cohort study.
Physiother Theory Pract
August 2024
Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Dokuz Eylül University, İzmir, Turkey.
Background: Flare Assessment in Rheumatoid Arthritis (FLARE-RA) is a patient-reported outcome measure (PROM) to evaluate the flare-related symptoms of individuals with Rheumatoid Arthritis (RA) in the last three months.
Objective: The present study aimed to demonstrate the translation, cultural adaptation and psychometric properties of the Turkish version of the FLARE-RA.
Methods: A cross-sectional psychometric analysis study was conducted with a total of 80 patients (61 Women, 19 Men; 49.
Clin Rheumatol
January 2023
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Flare Assessment in Rheumatoid Arthritis (FLARE-RA) is a self-administered tool aiming to capture current or recent flares in rheumatoid arthritis (RA). We aimed to externally validate the FLARE-RA instrument and its existing cutoffs for flare detection within a bDMARD-tapering context in established RA. Data were analyzed from the Tapering Etanercept in Rheumatoid Arthritis (TapERA) trial, which studied the feasibility of tapering etanercept in patients with established RA in sustained remission.
View Article and Find Full Text PDFRheumatology (Oxford)
December 2021
Rheumatology Department, Pitié Salpêtrière hospital, Sorbonne Université - Assistance Publique Hôpitaux de Paris, Paris, France.
Objective: The Flare Assessment in RA (FLARE-RA) self-administered questionnaire aims to identify patients who had flare in the interval between two consultations. This study aimed to establish a threshold for FLARE-RA score to identify RA flare.
Methods: The Tocilizumab SubCutAneous study evaluated the efficacy and safety of s.